Medical Imaging
Ventripoint to Showcase AI-Powered Cardiac Imaging at European Paediatric Cardiology Conference
Ventripoint will exhibit its VMS+ 4.0 technology at the AEPC annual meeting, highlighting its potential to improve lifelong care for congenital heart disease patients through accurate, MRI-equivalent assessments from echocardiograms.
Stress Cardiac MRI Testing Improves Angina Diagnosis and Patient Outcomes, Study Finds
New research presented at the American Heart Association's Scientific Sessions 2025 demonstrates that stress cardiac MRI testing significantly improves diagnosis accuracy and quality of life for patients with chest pain despite clear coronary arteries.
Voyageur Pharmaceuticals Appoints Financial Veteran Virginia Alling to Board, Accelerating U.S. Market Strategy
Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling to its board of directors, strengthening its financial expertise to drive U.S. market expansion and capital market access for its pharmaceutical-grade barium and iodine contrast media products.
Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Distribution Partnership
Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Mexican company Phalanx to expand access to its barium-based contrast media products in Latin America, representing a strategic move to address growing demand for cost-effective medical imaging solutions in underserved markets.
Izotropic Corporation Advances 3D AI-Imaging Technology in Growing $9 Billion Market
Izotropic Corporation is developing the IzoView Breast CT Imaging System, which combines high-resolution volumetric imaging with proprietary AI reconstruction to enhance breast cancer detection capabilities in a rapidly expanding medical imaging market.
Izotropic Corporation Featured in Editorial on AI-Driven Breast Cancer Imaging Innovation
Izotropic Corporation is highlighted in a NetworkNewsWire editorial focusing on how artificial intelligence is transforming breast cancer detection, particularly through the company's IzoView Breast CT Imaging System designed to improve accuracy for women with dense breast tissue.
Izotropic Corporation Outlines Commercialization Strategy for IzoView Breast CT Platform
Izotropic Corporation's CEO details the company's 12-18 month commercialization plan for its breast CT imaging technology, including FDA clinical studies and European market expansion, which could significantly improve breast cancer detection and treatment.
AI-Driven Imaging Technology Targets Breast Cancer Detection Challenges in High-Growth Market
Artificial intelligence is transforming breast cancer detection by addressing limitations in traditional imaging methods, particularly for women with dense breast tissue, as companies develop advanced diagnostic solutions for a market facing significant patient demand.
Izotropic Corp. Advances Breast CT Technology to Address Critical Gaps in Cancer Screening
Izotropic Corporation is developing compression-free 3D breast CT imaging technology to overcome limitations in current screening methods, particularly for women with dense breast tissue, during Breast Cancer Awareness Month.
Izotropic Corporation Featured in Editorial on AI-Driven 3D Imaging for Breast Cancer Detection
Izotropic Corporation's inclusion in a NetworkNewsWire editorial highlights how the company's AI-powered 3D breast imaging technology addresses critical detection challenges in the growing $9 billion medical imaging market.
AI-Enhanced 3D Imaging Technologies Transform Breast Cancer Detection in $9 Billion Market
Artificial intelligence is revolutionizing breast cancer diagnostics through advanced 3D imaging technologies that improve detection accuracy, particularly for women with dense breast tissue, addressing a critical global health challenge affecting millions of women annually.
AI-Enhanced 3D Imaging Technology Poised to Transform Breast Cancer Detection in $9 Billion Market
Artificial intelligence is revolutionizing breast cancer diagnostics through advanced 3D imaging technologies that offer improved detection accuracy, particularly for women with dense breast tissue, addressing a critical global health challenge affecting millions of women annually.
Izotropic Corporation Launches IzoView Breast CT Imaging System to Transform Cancer Detection
Izotropic Corporation has introduced its IzoView Breast CT Imaging System, a next-generation technology that addresses limitations of traditional mammography by providing 360-degree 3D visualization without compression, potentially revolutionizing breast cancer screening particularly for women with dense breast tissue.
Izotropic Corp Advances AI-Powered Breast CT Technology to Address Radiation Concerns in Cancer Screening
Izotropic Corporation is developing an AI-native breast CT imaging system that addresses radiation exposure concerns while improving diagnostic accuracy through advanced technology integration.
Izotropic Corp. Advances Breast CT Technology with Personalized Radiation Dosing and Strategic Funding
Izotropic Corp. is accelerating commercialization of its innovative breast CT system featuring personalized radiation dosing technology, positioning the company to capture market share in the projected $8.69 billion global breast imaging market by 2030.
Izotropic Corporation Highlights Critical Need for Advanced Breast Imaging Technology During Awareness Month
Izotropic Corporation emphasizes the limitations of current breast cancer screening tools and the potential of its IzoView Breast CT Imaging System to address diagnostic challenges, particularly for women with dense breast tissue, as global breast cancer cases continue to rise.
CMS Decision on CT Radiation Standards Highlights Industry Shift Toward Low-Dose Imaging Technology
The CMS proposal to keep CT radiation dose tracking voluntary underscores the ongoing tension between regulatory requirements and clinical needs, positioning companies like Izotropic with their low-dose breast CT technology at the forefront of evolving imaging standards.
Izotropic Corporation Highlights AI's Transformative Role in Breast Imaging with New Technology Platform
Izotropic Corporation's new feature article emphasizes how its IzoView Breast CT Imaging System is positioned to revolutionize breast cancer screening through AI integration, addressing limitations of traditional mammography systems.
Izotropic CEO Discusses Breast CT Imaging Breakthrough on BioMedWire Podcast
Izotropic Corporation's CEO Robert Thast revealed how the company's Breast CT technology can detect cancers as small as two millimeters and outlined European-first commercialization plans during a recent podcast interview.
Izotropic Integrates Personalized Radiation Dosing into Breast CT System, Positioning for Global Market Expansion
Izotropic Corporation has integrated a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, representing a significant advancement in breast cancer imaging technology with potential to improve patient safety and comfort while positioning the company for growth in the $8.69 billion global breast imaging market.
Izotropic Corporation Launches FAQ Page to Enhance Investor Transparency on Breast CT Technology
Izotropic Corporation has launched a comprehensive FAQ page to improve investor engagement and provide detailed information about its breast cancer detection technology and competitive positioning.
Izotropic's Proprietary AI Algorithm Trained on 15 Years of Breast CT Data Positions Technology to Redefine Global Imaging Standards
Izotropic Corporation has developed a proprietary machine-learning reconstruction algorithm using 15 years of breast CT data, creating sustainable competitive advantages in medical imaging through trade secret protection and modality-specific training.
Izotropic Secures Exclusive CADx Patent for AI-Enhanced Breast CT Imaging
Izotropic Corporation has obtained exclusive U.S. patent rights for computer-aided diagnosis with breast CT technology, positioning its IzoView system as a first-mover in AI-enhanced breast imaging with potential dual revenue streams through software upgrades and licensing.
Izotropic Corporation Featured in MarketScreener Editorial on AI Applications in Healthcare
Izotropic Corporation's breast cancer imaging technology is highlighted as a promising AI-driven medical advancement with potential to establish new standards in cancer care.
Izotropic Corporation's IzoView Breast CT Aims to Transform Dense Breast Tissue Imaging Amid $8.7B Market Opportunity
Izotropic Corporation is developing the IzoView Breast CT system to address limitations in traditional mammography for patients with dense breast tissue, potentially reducing missed cancers and unnecessary follow-up costs in the $8.7 billion global breast imaging market.
Izotropic CEO Highlights Breast CT Imaging Breakthrough in Podcast Interview
Izotropic Corporation's CEO discussed the company's IzoView Breast CT Imaging System, which can detect breast cancers as small as 2 millimeters, potentially revolutionizing early detection and positioning the company as a takeover target.
Izotropic Launches BreastCT.com Educational Platform to Address Market Education Challenge for Breast Imaging Technology
Izotropic Corporation has launched BreastCT.com as a strategic educational platform to address the critical market awareness challenge facing breakthrough medical technologies, particularly for its IzoView breast CT system designed for dense breast tissue imaging.
Izotropic Corporation Integrates AI Algorithm into Breast CT Imaging System to Enhance Clinical Efficiency
Izotropic Corporation has integrated a proprietary AI-based machine-learning reconstruction algorithm into its IzoView Breast CT Imaging System, developed with Johns Hopkins University, to improve image quality while maintaining low radiation doses and addressing workflow limitations of conventional methods.
Izotropic Corp. Launches Brand Transformation Ahead of Breast CT Technology Commercialization
Izotropic Corporation has unveiled a comprehensive brand identity transformation to position itself for the commercial launch of its revolutionary breast CT imaging technology targeting the $8.7 billion global breast imaging market.
Izotropic's $500K Breast CT System Challenges $8.7B Imaging Market with Lower Costs and Superior Technology
Izotropic Corporation's IzoView Breast CT system offers 360-degree 3D imaging without compression at up to 67% lower cost than competitors, potentially transforming breast cancer screening for women with dense breast tissue and reducing the $8 billion annual burden of inconclusive results.